Presentation is loading. Please wait.

Presentation is loading. Please wait.

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Published byTalon Shugar Modified over 10 years ago

Similar presentations

Presentation on theme: "Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients."— Presentation transcript:

1 Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias Blood Volume 122(14):2412-2424 October 3, 2013 ©2013 by American Society of Hematology

2 Transient mobilization of lymphocytes in MCL patients treated with ibrutinib. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

3 CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

4 Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

5 Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

6 Ibrutinib inhibits BCR-activated adhesion of MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

7 Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

8 Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells. Chang B Y et al. Blood 2013;122:2412-2424 ©2013 by American Society of Hematology

Download ppt "Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients."

Similar presentations

Wilson WH et al. Proc ASH 2012;Abstract 686.

Wilson WH et al. Proc ASH 2012;Abstract 686.
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):3102-3111.

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
CLL Stromal cell protect Conventional therapies Versteckspiel im Wald by Friedrich Eduard Meyerheim (1808-1879) The “outside” (microenvironment) of the.

CLL Stromal cell protect Conventional therapies Versteckspiel im Wald by Friedrich Eduard Meyerheim ( ) The “outside” (microenvironment) of the.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
Ibrutinib (PCI-32765) First-In-Class BTK Inhibitor IM Los Angeles 18 Jan 2013 1.

Ibrutinib (PCI-32765) First-In-Class BTK Inhibitor IM Los Angeles 18 Jan
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.

SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.
Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.

Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul.

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul.
Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells by Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman Blood.

Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells by Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman Blood.
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,

Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
PI 3-kinase inhibition has no effect on ANG II induced extracellular recognition kinase (ERK) 1/2 activation. PI 3-kinase inhibition has no effect on ANG.

PI 3-kinase inhibition has no effect on ANG II induced extracellular recognition kinase (ERK) 1/2 activation. PI 3-kinase inhibition has no effect on ANG.
IMBRUVICA® (ibrutinib)

IMBRUVICA® (ibrutinib)
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.
TCR-MHC-peptide(s): in vivo veritas

TCR-MHC-peptide(s): in vivo veritas

Similar presentations

Ads by Google